Conference Coverage

PPIs triple heart failure hospitalization risk in atrial fib patients


 

AT HEART FAILURE 2017

– Unwarranted prescriptions for proton pump inhibitors tripled the rate at which patients with atrial fibrillation needed hospitalization for a first episode of acute heart failure, in a retrospective study of 172 patients at a single center in Portugal.

About a third of the atrial fibrillation patients received a proton pump inhibitor (PPI) without a clear indication, and the PPI recipients developed heart failure at 2.9 times the rate as patients not on a PPI, a statistically significant difference, João B. Augusto, MD, reported at a meeting held by the Heart Failure Association of the European Society of Cardiology. Dr. Augusto believes that these patients largely had no need for PPI treatment, and the drug may have cut iron and vitamin B12 absorption by lowering gastric acid, resulting in deficiencies that produced anemia, and following that, heart failure, he suggested.

Dr. João B. Augusto,a cardiologist at Fernando da Fonseca Hospital in Amadora, Portugal Mitchel L. Zoler/Frontline Medical News

Dr. João B. Augusto

Iron and vitamin B12 deficiencies caused by PPI treatment provide “the best explanation” for the strong link the data showed between PPI use and new onset heart failure in this vulnerable patient population, said Dr. Augusto, a cardiologist at Fernando da Fonseca Hospital in Amadora, Portugal. The findings suggest that in practice “PPI use in patients with atrial fibrillation needs to be carefully weighed,” he said.

The study focused on 423 patients admitted to Fernando da Fonseca Hospital during January 2014–June 2015 with a primary or secondary diagnosis of atrial fibrillation. He excluded 101 patients with a history of heart failure, 109 patients on antiplatelet therapy, and 33 patients with a clear need for PPI treatment because of a gastrointestinal condition. Another 11 patients were lost to follow-up, leaving 172 patients followed for 1 year.

At the time of their initial hospitalization, 53 patients (31%) received a prescription for a PPI despite having no gastrointestinal diagnosis, likely a prophylactic step for patients receiving an oral anticoagulant, Dr. Augusto said. The patients averaged 69 years old, and nearly two-thirds were men.

During 1-year follow-up, the incidence of hospitalization for acute heart failure was 8% in the patients not on a PPI and 23% among those on a PPI, a statistically significant difference. In a regression analysis that controlled for age and chronic kidney disease, the incidence of acute heart failure was 2.9 times more common among patients on a PPI, Dr. Augusto said. He and his associates used these findings to educate their hospital’s staff to not needlessly prescribe a PPI to atrial fibrillation patients.

Dr. Augusto had no disclosures.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Recommended Reading

Neurosurgery at the End of Life
MDedge Hematology and Oncology
Families perceive few benefits from aggressive end-of-life care
MDedge Hematology and Oncology
David Bowie’s death inspires blog on palliative care
MDedge Hematology and Oncology
Neurosurgeon memoir illuminates the journey through cancer treatment and acceptance of mortality
MDedge Hematology and Oncology
STS: Minimizing LVAD pump thrombosis poses new challenges
MDedge Hematology and Oncology
Breast cancer treatment linked to mild systolic dysfunction
MDedge Hematology and Oncology
Allogeneic stem cells show promise for treating nonischemic dilated cardiomyopathy
MDedge Hematology and Oncology
Mixed findings on iron repletion in HF
MDedge Hematology and Oncology
New-onset AF boosts bad HFrEF outcomes
MDedge Hematology and Oncology
Cell sheet transplantation improves ischemic cardiomyopathy at 1 year
MDedge Hematology and Oncology